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INTRODUCTION
Sarcoidosis is a multisystem granulomatous disease of un-
known etiology characterized by the presence of noncaseat-
ing granulomas in involved organs. Although primarily in-
volving the eyes, lungs, ears, skin, and lymph nodes, many
other places in the body are also affected by this disease. Ocu-
lar involvement has been observed in 25-60% of patients
with systemic sarcoidosis (1). Although sarcoidosis may affect
nearly all ocular structures, the most common ocular mani-
festations are uveitis (30-70%) and conjunctival nodules
(40%) (1-5). However, this percentage depends on the pop-
ulation studied and the extent of ocular examination.
Sarcoidosis occurs worldwide but is prominent in certain
ethnic and racial groups, including African-Americans, Scan-
dinavians and Irish (6). The prevalence of sarcoidosis in the
Korean population is less than one (0.13) in 100,000, which
is far less than the 4 per 100,000 observed in the Japanese
population (7, 8). Involvement of the eyes also varies accord-
ing to ethnic background and race, with anterior uveitis more
frequent in black patients and posterior uveitis more frequent
in whites (1, 2, 4, 5). Ocular sarcoidosis is very rare in south-
east Asians, and there has been little analysis in Asian popu-
lations (7-9). We have therefore evaluated the incidence and
characteristics of ocular sarcoidosis in a Korean population.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 104
consecutive patients (65 women, 39 men) with biopsy-proven
sarcoidosis evaluated at Asan Medical Center, Seoul, Korea,
from 1993-2007. Sources of tissue for biopsy included lung
in 73 patients (71.9%), skin in 15 patients (13.4%), and lymph
node in 16 patients (14.7%). The study was approved by the
Institutional Review Board at Asan Medical Center. Records
of patients diagnosed with sarcoidosis were retrieved from
the hospital database. All patients were referred by either a
pulmonologist (94 patients) or a general ophthalmologist
(10 patients) and a complete history and ophthalmic exami-
nation were performed. 
Of the 104 patients, 22 patients (39 eyes) had active or inac-
tive ocular involvement. Inactive ocular involvement was
based on previous history of ocular involvement and ocular
change including keratic precipitates or iris synechiae. For
each patient, we recorded demographic data, including gen-
der, age at the time of initial examination, non-ocular and
ocular symptom and signs, treatment, and complications. 
Ocular involvement was classified anatomically according
to International Uveitis Study group criteria as isolated ante-
rior uveitis, intermediate uveitis (presence of anterior vitre-
ous cells, snow-balls, or snowbanks), retinal vasculitis with
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Ocular Sarcoidosis in a Korean Population
The aim of current study was to evaluate the incidence and characteristics of ocu-
lar sarcoidosis in a Korean population. We conducted a retrospective study of 104
consecutive patients with biopsy-proven sarcoidosis seen at Asan Medical Center
in Seoul, Korea, from 1993 to 2007. Medical records, photographs, and fluorescein
angiograms were reviewed. Of 104 patients, 22 (21%) had intraocular involvement
with female predominance (86%, M:F=3:19). Of the 39 eyes with ocular involve-
ment, 16 (41%) eyes had isolated anterior uveitis, 12 (31%) eyes had intermediate
uveitis, 6 eyes (15%) had panuveitis with retinal vasculitis, and 5 (13%) eyes had
panuveitis with punched multifocal choroiditis. Mean duration of ophthalmologic
follow-up was 62 months. All ocular inflammation was well managed with topical
steroid and/or systemic steroid with relatively good final visual outcomes. Ocular
complications such as cataract (12 eyes, 30%), glaucoma (6 eyes, 15%), vitreous
opacity (1 eye, 3%), cystoid macular edema (3 eyes, 7%), neovascularization (2
eye, 5%), and epiretinal membrane (4 eye, 10%) were related to ocular sarcoido-
sis. In Korea, where sarcoidosis is very rare, our study indicates relatively low ocu-
lar and predominantly non posterior segment involvement with relatively good visu-
al prognosis. 
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multifocal choroiditis (punched out chorioretinal scarring
with or without evidence of posterior segment inflammation
such as vitritis or cystoid macular edema) (10).
Statistical analysis
The prognostic factors considered were age, gender, type
of uveitis and initial visual acuity. The relationships between
these factors and poor visual outcome were statistically ana-
lyzed by means of the Mann-Whitney U test and Spearman
rank correlation test. A P value <0.05 was defined as statis-
tically significant. 
RESULTS
We identified 39 eyes of 22 patients (19 women, 3 men)
with a diagnosis of active (34 eyes) or inactive (5 eyes) ocular
sarcoidosis; their clinical and demographic characteristics are
shown in Table 1. Of the 22 patients, 9 patients presented
to the eye clinic with ocular symptoms as an initial symp-
tom of systemic sarcoidosis. In 12 patients, diagnoses of sys-
temic sarcoidosis preceded ocular sarcoidosis. The mean age
at initial examination was 43 yr (range, 23-62 yr). The mean
duration of follow up was 49 months (range 4-94) at depart-
ment of pulmonary medicine and 62 months (range 4-105)
at department of ophthalmology. Ten patients (45%) were
<40 yr of age, 3 (14%) were 40-54 yr of age, and 9 (40%)
were >55 yr showing bimodal peak in age. 
Ophthalmologic manifestations of 22 patients with ocular
involvement were summarized in Table 2. Bilateral ocular
involvement was seen in 17 patients (77%) and it was not
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*, Total pulmonary follow-up.
O, ocular; NO, non-ocular; LAP, lymphadenopathy at chest radiograph; PI, pulmonary infiltration; ACE (U/L), angiotension converting enzyme level
(reference range <40 U/L); NA, not available.
Total 
follow-up*
(month)
Laboratory
findings
Age (yr)/
gender
Initial 
symptom
Nonocular 
symptoms
Ocular symptoms
Patient
No.
Duration
between O and
NO diagnosis
(month)
1 60/F O None Ocular pain, floater 52 0 LAP, ACE (75)
2 46/F NO Fatigue None 94 0 LAP, ACE (90)
3 42/F O None Visual loss f/u loss 0 LAP, ACE (104)
4 32/M NO Weight loss, cough None 65 0 LAP, ACE (62)
5 33/F O None Photopsia, floater 48 3 LAP, ACE (20)
6 55/F NO Fever None 84 0 LAP, ACE (96)
7 27/F O None Visual loss 4 0 LAP, ACE (84)
8 27/F NO Cough None 55 0 LAP, ACE (52)
9 29/F NO Cough None 64 0 LAP, ACE (68)
10 31/F O None Ocular pain 48 12 LAP, ACE (38)
11 23/F NO Dyspnea None 32 0 LAP, ACE (93)
12 59/F NO Fatigue Visual loss 36 0 LAP, ACE (57)
13 26/F NO Dyspnea Photopsia 53 0 LAP, ACE (61)
14 44/F O None Visual loss 44 18 LAP, ACE (71)
15 55/F NO Dyspnea Visual loss 56 0 LAP, ACE (82)
16 30/F NO Epigastric discomfort None 84 0 LAP, ACE (122)
17 56/F O None Floater 12 0 LAP, ACE (61)
18 56/F O None Visual loss 9 0 LAP
19 28/F NO None None 63 0 LAP, ACE (173)
20 57/F NO Dyspnea Visual loss 78 0 PI, ACE (148)
21 60/F O None Visual loss 27 12 NA
22 62/F O None Visual loss 30 0 LAP, ACE (48)
Table 1. Profile of 22 sarcoidosis patients with ocular involvement 
Fig. 1. Comparision of age among four ordered types of uveitis.
While anterior or intermediate uveitis tend to occur in younger age
group, all 3 patients (5 eyes) showing ‘panuveitis with punched
multifocal choroiditis’ were over 55 yr old. 
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*, recurrent inflammation; 
� , total ophthalmologic follow-up; 
� , cataract operation; 
�, cataract operation, pars plana vitrectomy due to vitreous opacity;
‖, cataract operation, Ahmed valve implantation due to neovascular glaucoma.
AU, anterior uveitis; IU, intermediate uveitis; (U), previous history of uveitis; (AU), previous history of anterior uveitis; (RV), previous history of retinal vas-
culitis; RV, retinal vasculitis; MC, multifocal choroiditis; Cell, cell in anterior chamber; Flare, flare in anterior chamber; KP, keratic precipitate; Mutton
KP, mutton-fal keratic precipitate; D-F nodule, Dalen-Fuchs nodule; T, topical steroid treatment; S, systemic steroid treatment; (S), previous history of
systemic steroid treatment; L, local steroid treatment; (PRP), previous history of panretinal photocoagulation; CF, count finger; NLP, no light percep-
tion; CAT, cataract; ERM, epiretinal membrane; NV, neovascularization; CME, cystoid macular edema; NVG, neovascular glaucoma.
Initial
VA
Last
VA
Ocular
complications
Ocular
inflammation
Ocular
findings
Treatment
Duration
of illness
(month)/R*
Total
follow-up
�
(month)
Patient No.
/laterality
1/right AU C&F, KP S/T 2/R 52 0.8 0.8 CAT
1/left AU C&F, KP S/T 2 0.8 1.0 CAT
2/right AU Cell (S), T 1 84 1.0 1.0 Glaucoma
2/left AU Ant. syneciae (S), T 1 1.0 1.0
3/left IU C&F, KP S/T NA f/u loss 0.8 NA
4/right IU Cell, vitritis T 1 65 0.8 0.8
4/left AU Cell T 1 0.8 1.0
5/right (U), AU Flare (S), T 1 48 0.8 1.0
5/right (U), AU Flare (S), T 1 0.8 1.0 CAT
6/right AU C&F, KP S/T 1 105 0.32 1.0
6/left AU C&F, KP S/T 1 0.63 CF Glaucoma
7/left (AU) Mutton KP None NA 4 0.2 NA
8/left (AU) Pigment on lens (S) NA 55 1.0 1.0
9/right (IU) Flare None NA 64 0.5 1.0
10/right (U), AU C&F, KP S/T/L 11 79 1.0 1.0
10/left IU C&F, KP, Ant synechiae S/T/L 11 0.16 0.8
11/right IU Cell, Vitritis S/T 4/R 74 0.8 0.8
11/left IU Cell, Vitritis S/T 4/R 0.8 1.0
12/right IU Cell, Vitritis S/T 2 91 1.0 0.8 CAT
12/left IU Cell, Vitritis S/T 2 0.5 0.8 CAT
13/right AU Cell S 1 53 0.8 0.63
13/left AU Cell S 1 0.8 0.63
14/right IU Cell, KP, vitritis S/T 14/R 81 0.8 1.0 Glaucoma
14/left IU Cell, KP, vitritis S/T 14/R 0.8 1.0 Glaucoma
15/right (RV) KP (PRP)/S NA/R 104 0.08 0.08 Glaucoma,
CAT, ERM
15/left (RV) KP (PRP)/S NA NLP NLP NVG, enucleation
16/right AU Cell, KP T 2 84 1.2 1.2
16/left RV Cell, KP T 2 1.2 1.2
17/right RV Cell, vasculitis, granuloma S/T/L 12 12 0.5 0.5 CME, ERM
17/left RV Cell, vasculitis, granuloma S/T/L 12 0.63 0.63 CME, ERM
18/right (U), RV Vitritis, vasculitis S/T 3/R 65 0.2 0.5 CME
19/right IU Cell, vitritis S/T 1 63 0.8 0.63
19/left IU Cell, vitritis S/T 1 0.8 1.0
20/right MC Cell, KP, D-F nodule S/T 3 78 0.63 1.0 CAT
20/left AU Cell, KP S/T 3 0.8 0.4 CAT
21/right (U), MC D-F nodule S/T/L 2/R 27 0.25 0.5 CAT, operation
�
21/left MC D-F nodule S/T/L 2/R 0.1 0.5 CAT, operation
�
22/right (U), MC Cell, D-F nodule S/T 4/R 30 0.2 0.5 CAT, operation
�
ERM
22/left MC Cell, D-F nodule S/T 4/R 0.1 0.4 CAT, NVG,
operation
‖
Table 2. Ophthalmologic manifestations of 39 eyes of 22 ocular sarcoidosis patientsalways symmetrical. Of 39 eyes, 16 (41%) had anterior uvei-
tis, 12 (31%) had intermediate uveitis and 11 (28%) had pos-
terior involvement, which was classified as, panuveitis with
retina vasculitis in 6 (15%) (Fig. 2) and panuveitis with pun-
ched multifocal choroiditis in 5 (13%) (Fig. 3). Age compar-
isons among the four types of uveitis are presented in Fig. 1.
Interestingly, all 3 patients (5 eyes) showing panuveitis with
punched multifocal choroiditis were women over 55 yr old. 
Of 34 eyes with active ocular involvement, four eyes (11%)
were exposed to previous systemic steroid treatment. The
ophthalmic inflammation was managed with topical steroids
alone in 8 eyes (24%) and/or with systemic corticosteroids
in 26 eyes (76%). Six (31%) eyes with recurrent panuveitis
or advanced to intermediate uveitis were treated with peri-
ocular corticosteroids, subtenon injection of triamcinolone,
which were sufficient to control the inflammatory response
without the use of additional immunosuppressive drugs. Mean
duration of illness was 3.8 months (range, 1-35) with recur-
rence in 11 eyes. The duration of illness only included that
of the first episode and with patient No. 19, it was marked
as 1 month but the patient was followed up furthermore due
to continuing inflammation by local clinic at a place in con-
nection with. All episodes including recurrences were man-
aged with steroid treatment. Systemic cytotoxic agent was
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Fig. 2. Patient No. 17. Fundus photographs (A, B) show retinal vasculitis and multiple depigmented peripheral lesions. Fluorescence angio-
graphy (FAG) (C, D) shows late fluorescein leakage from retinal vessels with adjacent capillary nonperfusion. 
A B
C Dnot required either for ophthalmological treatment or for pul-
monary treatment. 
Ten eyes (26%) developed cataract; one of these patients
(Patient No. 22) had cataract extraction in both eyes with
intraocular lens implantation. Six eyes (15%) had glaucoma,
which was treated medically; one of these eye (Patient No. 6)
required additional treatment to control the intraocular pres-
sure, but this patient refused surgery and the other patient
(Patient No. 22) required Ahmed valve implantation due to
neovascular glaucoma. Three eyes developed either cystoid
macular edema or epiretinal membrane followed by posteri-
or segment involvements which were observed without fur-
ther treatment due to the risk of possible further treatment.
One eye underwent vitrectomy for vitreous opacity. 
Poor visual outcome was significantly more frequent in
patients with posterior segment involvement including panu-
veitis with retinal vasculitis or panuveitis with multifocal
choroiditis than in patients with anterior/intermediate uveitis
(P<0.05). Also visual outcome was worse in the old aged group
(P<0.05). Lower visual acuity at initial examination or gender,
however, did not affect the visual outcome at last follow-up. 
DISCUSSION
We have reviewed the medical records of patients seen at
the Asan Medical Center with biopsy-proven sarcoidosis to
investigate the characteristics of ocular sarcoidosis in Kore-
ans. Although sarcoidosis remains very rare in Koreans, only
309 biopsy-proven cases were reported between July 1992
and June 1999 in the second nationwide survey, we identified
a sufficient number of patients for analysis having an advan-
tage of utilizing the largest pool of the sarcoidosis patients
in Korea (8). 
We found that ocular involvement was relatively low in the
present study with sarcoidosis (21%), lower than in US and
European populations (20-30%) (1, 11-13) and much lower
than in Japanese patients with systemic sarcoidosis (50-80%)
(1, 11-15). We also observed a significantly higher female
predominance in ocular involvement (M:F=3:19), when com-
pared with previous studies (M:F=1:2-3) (11, 16, 17). Fur-
thermore, all 3 patients with panuveitis and multifocal cho-
roiditis were females older than 55 yr. White females also
seem to be a distinct clinical subgroup of patients with ocu-
lar sarcoidosis (18-20). In elderly white female patients, panu-
veitis and multifocal choroiditis was predominantly associ-
ated with the occurrence of cystoid macular edema (72%)
and visual loss (42%) (12, 19). Our findings also suggest that
elderly patients are more likely to have relatively poor visual
outcomes. 
In the present study, posterior segment involvement was
28%, which is comparable to previous results, in which the
rate of posterior segment involvement varied from 25% to
94% (12, 21, 22). Although our study showed relatively good
visual outcome in patients with ocular involvement, poste-
rior involvement, age and presence of ocular complication
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Fig. 3. Patient No. 21. Fundus photographs show subacute multifocal choroiditis with accompanying vitreous opacity at initial presentation
(A, B) and residual choroiditis accompanying atrophic change at one month later (C, D). Fluorescence angiography of right inferonasal
aspect and left posterior pole of retina at one month later from initial presentation (E, F) show atrophic choroidal changes. 
A B C
D E Frelated to inflammation were significantly related to relative-
ly visual outcome. Previous studies also found that poor visu-
al outcome was significantly more frequent in patients with
panuveitis and multifocal choroiditis and that visual loss was
caused by cataract, glaucoma, macular edema, vitreous hem-
orrhage, and retinal detachment (18). 
Corticosteroids are the mainstay of therapy for ocular sar-
coidosis. Cycloplegics are frequently needed to prevent syne-
ciae (12). Eye involvement was the most common reason for
systemic steroid therapy, followed in order by the lung and
heart involvement (23). Eight eyes (24%) were treated with
topical steroids alone, with systemic steroids used in patients
with ocular disease that included severe or topical treatment
resistant posterior uveitis. No further immunosuppressive
treatment was needed for management for ocular involve-
ment. However, during the follow-up there was recurrence
of ocular inflammation in 11 eyes which were also treated
with systemic and topical steroid. Overall, most patients with
ocular sarcoidosis in our study responded to topical or sys-
temic steroid therapy. 
Although duration between ophthalmologic and non-oph-
thalmologic diagnosis was remarked as 0 month, this was
because of routine referral to pulmonary or ophthalmologic
work-up when sarcoidosis is suspicious. Of 22 patients with
ocular involvement, 10 patients have been diagnosed with
sarcoidosis while management of ocular inflammation. Fur-
thermore, the rest of patients except two patients had active
ocular inflammation at the time of referral from pulmonary
specialist. Though ocular sarcoidosis is still very rare in Korea,
ophthalmic screening examination with high index of sus-
picion is warranted in patients with sarcoidosis. 
Korean sarcoidosis patients seemed to have similar patterns
of clinical characteristics such as bimodal peak in age and
associated ocular complications compared to western patients.
However, in contrast to western population, the rate of ocu-
lar involvement was relatively low, with higher female pre-
dominance and relatively better visual outcome. 
The limitations of this study included its retrospective
design, the small numbers of patients, observation in only
one institute and a description of only intraocular findings.
Prior to this study, however, there was no analysis of clinical
characteristics of ocular sarcoidosis in Koreans due to the rar-
ity of sarcoidosis among Koreans. Therefore, the data report-
ed here were accumulated over a 15-yr period and can be
recorded as the largest series of ocular sarcoidosis in a Kore-
an population. Moreover, considering that sarcoidosis is very
rare in Korea and the incidence of ocular involvement is rel-
atively low, the number of ocular sarcoidosis in our study pop-
ulation may represent the actual incidence of ocular sarcoido-
sis in Korea.
In conclusion, in Korea where sarcoidosis is very rare, our
study shows relatively low ocular involvement and relatively
low posterior segment involvement with female predomi-
nance. In general, visual prognosis is relatively good. Prompt
treatment with high index of suspicion of sarcoidosis-related
uveitis may improve visual prognosis.
REFERENCES
1. Hunter DG, Foster CS. Ocular manifestations of sarcoidosis. In:
Albert DM, Jakobiec FA, eds. Principles and Practice of Opthal-
mology. Philadelphia: WB Saunders, 1994; 1217-24.
2. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and
its ophthalmic manifestations. Am J Ophthalmol 1978; 86: 648-55.
3. James DG, Anderson R, Langley D, Ainslie D. Ocular sarcoidosis.
Br J Ophthalmol 1964; 48: 461-70.
4. Karma A. Ophthalmic changes in sarcoidosis. Acta Ophthalmol
Suppl 1979; 141: 1-94.
5. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am
J Ophthalmol 1986; 102: 297-301. 
6. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC.
Racial differences in sarcoidosis incidence: a 5-year study in a health
maintenance organization. Am J Epidemiol 1997; 145: 234-41.
7. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF,
du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Sel-
roos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on
sarcoidosis. American Thoracic Society/European Respiratory Soci-
ety/World Association of Sarcoidosis and other Granulomatous Dis-
orders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
8. Kim DS. Sarcoidosis in Korea: report of the second nationwide sur-
vey. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 176-80. 
9. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sar-
coidosis. What story do prevalence and incidence tell us? Clin Chest
Med 1997; 18: 681-94.
10. BenEzra D, Rorrester JV, Nussenblat RB. Uveitis Scoring System.
Berlin: Springer-Verlag, 1991; 1-13. 
11. James DG, Neville E, Langley DA. Ocular sarcoidosis. Trans Oph-
thalmol Soc U K 1976; 96: 133-9.
12. Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis HJ, Bree-
baart AC. Risk factors for ocular sarcoidosis. Doc Ophthalmol 1989;
72: 287-96.
13. Iwata K, Nanba K, Sobue K, Abe H. Ocular sarcoidosis: evaluation
of intraocular findings. Ann N Y Acad Sci 1976; 278: 445-54.
14. Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study
on sarcoidosis in Japan. Recent trends in incidence and prevalence
rates and changes in epidemiological features. Sarcoidosis 1989; 6:
138-46.
15. Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations
of systemic sarcoidosis. Jpn J Ophthalmol 1992; 36: 452-7.
16. Lobo A, Barton K, Minassian D, du Bois RM, Lightman S. Visual
loss in sarcoid-related uveitis. Clin Experiment Ophthalmol 2003;
31: 310-6. 
17. Khalatbari D, Stinnett S, McCallum RM, Jaffe GJ. Demographic-
related variations in posterior segment ocular sarcoidosis. Ophthal-
mology 2004; 111: 357-62.
18. Thorne JE, Brucker AJ. Choroidal white lesions as an early mani-
festation of sarcoidosis. Retina 2000; 20: 8-15.
418 S.Y. Lee, H.G. Lee, D.S. Kim, et al.19. Lardenoye CW, Van der Lelij A, de Loos WS, Treffers WF, Rotho-
va A. Peripheral multifocal chorioretinitis: a distinct clinical entity?
Ophthalmology 1997; 104: 1820-6.
20. Hershey JM, Pulido JS, Folberg R, Folk JC, Massicotte SJ. Non-
caseating conjunctival granulomas in patients with multifocal cho-
roiditis and panuveitis. Ophthalmology 1994; 101: 596-601.
21. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognos-
ticators for visual outcome in sarcoid uveitis. Ophthalmology 1996;
103: 1846-53.
22. Bardelli AM, Barberi L, Vanni M, Mazzera L, Traversi C. Eye in-
volvement in sarcoidosis: survey of 197 patients. Sarcoidosis 1993;
10: 158-9. 
23. Sugisaki K, Yamaguchi T, Nagai S, Ohmiti M, Takenaka S, Morimo-
to S, Ishihara M, Tachibana T, Tsuda T. Clinical characteristics of
195 Japanese sarcoidosis patients treated with oral corticosteroids.
Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 222-6. 
Ocular Sarcoidosis in a Korean Population 419